WTC
MCRB icon

WhitTier Trust Company’s Seres Therapeutics MCRB Stock Holding History

WhitTier Trust Company’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8 Buy
+1
New +$8 ﹤0.01% 1420
2016
Q4 		– Sell
-23
Closed -$6K – 968
2016
Q3 		$6K Hold
23
– – ﹤0.01% 809
2016
Q2 		$13K Buy
+23
New +$13.5K ﹤0.01% 740

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

WhitTier Trust Company's MCRB Position: Q2 2026 in Review

WhitTier Trust Company opened a new position in Seres Therapeutics (MCRB) in Q2 2026: 1 share worth $8. The stake represents ﹤0.01% of the portfolio and ranks #1420 among its holdings. This is a return to the name: WhitTier Trust Company previously reported a position in MCRB as recently as Q3 2016.

WhitTier Trust Company first reported a position in MCRB in Q2 2016 and has held it in 3 quarters since. The position peaked at $13K in Q2 2016. 35 funds tracked by Wall St. Rank hold MCRB as of Q2 2026.

  • WhitTier Trust Company held 1 share of Seres Therapeutics worth $8 as of Q2 2026.
  • Seres Therapeutics was a new WhitTier Trust Company position in Q2 2026.
  • Seres Therapeutics made up ﹤0.01% of WhitTier Trust Company's portfolio in Q2 2026, its #1420 holding.
  • WhitTier Trust Company first reported a position in Seres Therapeutics in Q2 2016 and has held it in 3 quarters since.
  • WhitTier Trust Company's Seres Therapeutics position peaked at $13K in Q2 2016.
  • 35 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2026.

Based on WhitTier Trust Company's 13F filing for Q2 2026, filed 28 Jul 2026.